Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox + Erythropoietin in Low/Int-1 Risk MDS
NCT01868477Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by Novartis. Started Jan 2014; status: completed.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01868477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01868477.